Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2586594 | 0.88 | LMNA (0.38) | PPARGMAPTRXRAMEN1KMT2A | |
| SCHEMBL6936638 | 0.86 | HSP90AB1 (0.36) | ALDH1A1GAAMAPTHTTMEN1 | |
| SCHEMBL6938641 | 0.84 | HSP90AB1 (0.41) | ALDH1A1GAAKDM4EHSP90AB1 | |
| SCHEMBL1387817 | 0.84 | PPARG (0.49) | PPARGALDH1A1KDM4EMAPTRXRA | |
| SCHEMBL6933096 | 0.83 | METAP1 (0.44) | PPARG | |
| SCHEMBL17853664 | 0.83 | PPARG (0.36) | PPARGALDH1A1KDM4EMAPTRXRA | |
| SCHEMBL3862066 | 0.83 | PPARG (0.36) | PPARGMAPTRXRAKMT2AACHE | |
| SCHEMBL28794754 | 0.81 | ALDH1A1 (0.47) | PPARGALDH1A1RXRAL3MBTL1LMNA | |
| SCHEMBL6932963 | 0.81 | GAA (0.40) | GAAHTTKMT2AHSP90AB1LMNA | |
| SCHEMBL6931403 | 0.81 | HPGD (0.34) | ALDH1A1GAAKDM4EMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102030642-A | Synthesis method and application of intermediate of sulindac analogue | UNIV XIAMEN | 2011-04-27 | — | — | CN | disclosed |
| US-20010020020-A1 | Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols | PAMUKCU RIFAT (US) | 2001-09-06 | — | — | US | disclosed |
| US-20010006965-A1 | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols | PAMUKCU RIFAT (US) | 2001-07-05 | — | — | US | disclosed |
| US-6177471-B1 | PHOSPHODIESTERASE INHIBITOR | CELL PATHWAYS, INC. | 2001-01-23 | — | — | US | disclosed |
| US-6028116-A | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-6025394-A | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols | CELL PATHWAYS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5965619-A | ADMINISTERING AN INDENE DERIVATIVE OF GIVEN FORMULA, SUCH AS 1-(2,4,6-TRIMETHOXYBENZYLIDENE)-5-DIMETHYLAMINO-2-METHYL-3-INDENYL ACETIC ACID, TO TREAT PRECANCEROUS LESIONS SUCH AS COLONIC ADENOMATOUS POLYPS; SIDE EFFECT REDUCTION | CELL PATHWAYS INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5958982-A | Method for treating patients with sarcoidosis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | CELL PATHWAYS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5902827-A | Method for treating patients with psoriasis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | CELL PATHWAYS (US) | 1999-05-11 | — | — | US | disclosed |
| EP-0206241-B1 | PROCESS FOR THE PREPARATION OF CIS-5-FLUORO-2-METHYL-1-(4-METHYLTHIOBENZYLIDENE)-INDENE-3-ACETIC ACID | ZAMBON S.p.A. (IT) | 1989-04-19 | — | — | EP | disclosed |
| US-4748271-A | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methyl-thiobenzylidene)-indene-3-acetic acid | ZAMBON S.P.A. (IT) | 1988-05-31 | — | — | US | disclosed |
| US-4656190-A | PLATELET ACTIVATING FACTOR | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0206241-A1 | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid | ZAMBON S.p.A. (IT) | 1986-12-30 | — | — | EP | disclosed |
| EP-0142801-A2 | Indene derivatives useful as paf-antagonists | MERCK & CO. INC. (US) | 1985-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020020-A1 | Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols | ALDH1A2, ALDH1A3, FFAR3 | PPARG 31/4885ALDH1A1 13/4885GAA 3425/4885 |
| US-20010006965-A1 | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols | ALDH1A2, ALDH1A3, IAPP | PPARG 32/4885ALDH1A1 25/4885GAA 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.